Drug Type Chemical drugs |
Synonyms BLX-0279, BLX0279 |
Target |
Action inhibitors |
Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Preclinical | United States | 23 Jan 2024 | |
| Amyotrophic Lateral Sclerosis | Preclinical | United States | 23 Jan 2024 | |
| Huntington Disease | Preclinical | United States | 23 Jan 2024 |





